MRNA leapfrogs DNA to show promise for therapeutic gene transfer

Molecular Therapy

Volumn 20, Issue 4, 2012, Pages 694-695

  Gilboa, Eli ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; DNA; ERYTHROPOIETIN; MESSENGER RNA; PLASMID DNA; POLYCATION; PSEUDOURIDINE; RECOMBINANT ERYTHROPOIETIN; SURFACTANT PROTEIN B; URIDINE; VIRUS VECTOR;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ANEMIA; ANTINEOPLASTIC ACTIVITY; BIOLOGICAL ACTIVITY; BLOOD CLOTTING DISORDER; CANCER CONTROL; COMPLEX FORMATION; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; ENZYME STABILITY; EXPERIMENTAL MODEL; GENE DOSAGE; GENE PRODUCT; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HEMATOCRIT; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; NOTE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; RETICULOCYTE COUNT; RNA ANALYSIS; RNA STRUCTURE; THERAPY EFFECT; TUMOR IMMUNITY;

EID: 84859393296     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.31     Document Type: Note

References (11)

1. Karikó, K, Muramatsu, H, Keller, JM and Weissman, D (2012). Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin. Mol Ther, in press.
2. Conry, RM, LoBuglio, AF, Wright, M, Sumerel, L, Pike, MJ, Johanning, F et al. (1995). Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res 55: 1397-1400.
3. Granstein, RD, Ding, W and Ozawa, H (2000). Induction of anti-tumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA. J Invest Dermatol 114: 632-636. (Pubitemid 30226992)
4. Kreiter, S, Diken, M, Selmi, A, Tureci, O and Sahin, U (2011). Tumor vaccination using messenger RNA: prospects of a future therapy. Curr Opin Immunol 23: 399-406.
5. Karikó, K, Ni, H, Capodici, J, Lamphier, M and Weissman, D (2004). mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem 279: 12542-12550. (Pubitemid 38445825)
6. Diebold, SS, Kaisho, T, Hemmi, H, Akira, S and Reis e Sousa, C (2004). Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303: 1529-1531. (Pubitemid 38314425)
7. Karikó, K, Muramatsu, H, Welsh, FA, Ludwig, J, Kato, H, Akira, S et al. (2008). Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 16: 1833-1840.
8. Kormann, MS, Hasenpusch, G, Aneja, MK, Nica, G, Flemmer, AW, Herber-Jonat, S et al. (2011). Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol 29: 154-157.
9. Karikó, K, Muramatsu, H, Ludwig, J and Weissman, D (2011). Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, proteinencoding mRNA. Nucleic Acids Res 39: e142.
10. Casadevall, N, Nataf, J, Viron, B, Kolta, A, Kiladjian, JJ, Martin-Dupont, P et al. (2002). Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346: 469-475. (Pubitemid 34441737)
11. Takeda, K, Kaisho, T and Akira, S (2003). Toll-like receptors. Annu Rev Immunol 21: 335-376. (Pubitemid 37174535)